For accredited investors only: Learn more about Balanced Pharma’s limited-time investment opportunity for healthcare professionals.

We're Balanced Pharma.

We're improving lives
by improving
patient comfort.

Highly differentiated, best-in-class pain relief drugs for surgical and dental procedures.

Current Product Pipeline

Target product profiles

BPI-004

BPI-004

Best-in-class post-surgical analgesic

BPI-004 (“Enduracaine”) is a non-opioid, single-dose injectable local analgesic that provides up to three days of pain relief following surgical procedures.

Oral & maxillofacial surgery, orthopedic surgery, general surgery, podiatric surgery, gynecological surgery, CT surgery

View Helping End the Opioid Crisis

View the 40-second video: Helping End the Opioid Crisis

BPI-004 has a retail revenue/income SAM over $5.2/$3.1 B.
$ 0 B SAM

BPI-001

BPI-001

Best-in-class local dental anesthetic

BPI-001 (“Libracaine”) is a best-in-class, injectable anesthetic for dental procedures that is significantly less painful, faster-acting, and more likely to get patients numb than the current drugs.

View our 80-second demo video

View the 80-second demo video

BPI-001 has a wholesale revenue/income SAM over $2.2/$1.5 B.
$ 0 B SAM

Traction

$10+ MM raised, including an $8 MM A round, led by the leading strategic in the dental anesthetic space

Recent Press

Septodont Invests in Balanced Pharma, Joins Board​

Featured in Dentistry Today | January 20, 2025
Septodont, the dominant global leader in dental anesthetics, has made a strategic investment in Balanced Pharma Inc. (“BPI”) as part of an institutional funding round, and Septodont COO Atif Zia has...

Balanced Pharma Analgesic Aims to Lower Opioid Use

Featured in Dentistry Today | November 12, 2024
Balanced Pharma Incorporated (BPI) has announced the acquisition of rights to a promising new non-opioid injectable post-surgical pain relief drug...

Howard Glazer, Scientific Advisory Board Member. More comfortable injections, less time in the dental chair, and more reliable anesthesia? Count me in.

Dr. Howard S. Glazer Joins Balanced Pharma

Featured in Conexiant | March 12, 2024
Leading dental educator predicts huge impact for patients, providers. Howard S. Glazer, DDS, FAGD has joined Balanced Pharma’s Scientific Advisory Board. Dr. Glazer, an award-winning, leading voice in dental education...

Balanced Pharma Expands Patent Portfolio for Less Painful Dental Anesthetic

Featured in Conexiant | December 21, 2023
Dentist-founded company receives additional U.S. patent for its dental cartridge technology...

For Accredited Investors Only

Become a Shareholder in Balanced Pharma

Limited investment opportunities may be available.

Please acknowledge the following to continue

I acknowledge that all Balanced Pharma Incorporated (BPI) products are currently in development and have not been evaluated or approved by FDA or any other regulatory body.

Products mentioned on this website are not available for sale, distribution, or use in any jurisdiction.

This website is for accredited investors only.

By continuing, you acknowledge the following: I am an accredited investor as defined by the U.S. Securities and Exchange Commission (SEC).

The information on this website is an overview and does not constitute an offer or invitation for the sale or purchase of securities or any of the businesses or assets described herein. Any BPI products mentioned are in developmental stage, have not been evaluated or approved by FDA or any other regulatory authority, and are not for sale in any jurisdiction or under any circumstance. Contact Balanced Pharma for more updated and detailed information about investment opportunities.